SCHEMBL2417403

SCHEMBL2417403

CCCCN(CCCC)C(=O)CC(C)=O

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA12 O43570 3/20 0.50
CA1 P00915 3/20 0.50
CA9 Q16790 3/20 0.50
MMP1 P03956 1/20 0.47
MMP2 P08253 1/20 0.47
MMP3 P08254 1/20 0.47
MMP8 P22894 1/20 0.47
SIGMAR1 Q99720 2/20 0.42
ALDH1A1 P00352 3/20 0.40
ALDH2 P05091 1/20 0.40
HDAC3 O15379 1/20 0.38
HDAC1 Q13547 1/20 0.38
HDAC2 Q92769 1/20 0.38
HDAC6 Q9UBN7 1/20 0.38
NCOR2 Q9Y618 1/20 0.38
KDM5A P29375 5/20 0.38
KDM4C Q9H3R0 4/20 0.38
HPGD P15428 1/20 0.38
CA2 P00918 1/20 0.38
POLB P06746 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30364158 0.98 CA12 (0.48) CA12CA1CA9MMP1MMP2
SCHEMBL14890557 0.98 CA12 (0.48) CA12CA1CA9MMP1MMP2
SCHEMBL15520237 0.98 CA12 (0.48) CA12CA1CA9MMP1MMP2
SCHEMBL30364182 0.98 CA12 (0.48) CA12CA1CA9MMP1MMP2
SCHEMBL29383768 0.98 CA12 (0.48) CA12CA1CA9MMP1MMP2
SCHEMBL15016405 0.98 CA12 (0.48) CA12CA1CA9MMP1MMP2
SCHEMBL19621298 0.96 SIGMAR1 (0.47) CA12CA1CA9MMP1MMP2
SCHEMBL16210777 0.94 CA12 (0.45) CA12CA1CA9MMP1MMP2
SCHEMBL2250218 0.92 CA12 (0.44) CA12CA1CA9MMP1MMP2
SCHEMBL11357421 0.91 CA12 (0.45) CA12CA1CA9MMP1MMP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 231 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-105646914-A Process for producing composites 赢创德固赛有限公司 2016-06-08 CN claimed
US-20160152825-A1 PROCESS FOR PRODUCING COMPOSITES EVONIK DEGUSSA GMBH (DE) 2016-06-02 US claimed
EP-3026072-A1 Method for the preparation of composites Evonik Degussa GmbH (DE) 2016-06-01 EP claimed
EP-4730479-A2 FLAME-RETARDANT NON-AQUEOUS ELECTROLYTIC SOLUTION AND SECONDARY BATTERY USING SAME Kyoto University (JP) 2026-04-22 EP disclosed
US-20260088410-A1 ELECTRONICS ASSEMBLY HAVING ELECTROCHEMICALLY DEBONDABLE COMPONENTS HENKEL AG & CO KGAA (DE) 2026-03-26 US disclosed
US-12540262-B2 Two component (2K) curable adhesive composition HENKEL AG & CO. KGAA (DE) 2026-02-03 US disclosed
EP-3807229-B1 PROCESS FOR THE PRODUCTION OF COMPOSITE ARTICLES NOURYON CHEMICALS INT BV (NL) 2025-10-22 EP disclosed
US-20250246685-A1 FLAME-RETARDANT NON-AQUEOUS ELECTROLYTIC SOLUTION AND SECONDARY BATTERY USING SAME KYOTO UNIVERSITY (JP) 2025-07-31 US disclosed
WO-2025119646-A1 BONDED STRUCTURE COMPRISING AN ELECTROCHEMICALLY DEBONDABLE ADHESIVE HENKEL AG & CO. KGAA (DE) 2025-06-12 WO disclosed
WO-2025120994-A1 SECONDARY BATTERY NON-AQUEOUS ELECTROLYTE AND SECONDARY BATTERY PROVIDED WITH SAME ステラケミファ株式会社 2025-06-12 WO disclosed
EP-4566808-A1 BONDED STRUCTURE COMPRISING AN ELECTROCHEMICALLY DEBONDABLE ADHESIVE Henkel AG & Co. KGaA (DE) 2025-06-11 EP disclosed
WO-2012126919-A1 PROCESS FOR THE PREPARATION OF AN ACCELERATOR SOLUTION AKZO NOBEL CHEMICALS INTERNATIONAL B.V. (NL) 2012-09-27 WO disclosed
WO-2011117225-A1 FE(III) COMPLEX COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF IRON DEFICIENCY SYMPTOMS AND IRON DEFICIENCY ANEMIAS VIFOR (INTERNATIONAL) AG (CH) 2011-09-29 WO disclosed
WO-2011117225-A1 FE(III) COMPLEX COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF IRON DEFICIENCY SYMPTOMS AND IRON DEFICIENCY ANEMIAS VIFOR (INTERNATIONAL) AG (CH) 2011-09-29 WO disclosed
US-20110070657-A1 DETECTING IONS AND MEASURING ION CONCENTRATIONS THE GENERAL HOSPITAL CORPORATION (US) 2011-03-24 US disclosed
WO-2003082978-A1 COLD CURABLE RESIN COMPOSITION, CURING METHOD OF THE RESIN COMPOSITION AND CURED PRODUCT OF THE RESIN COMPOSITION DJK LABORATORIES INC. (JP) 2003-10-09 WO disclosed
EP-0748310-B1 DIESTERS OF CARBONIC ACID ENDOWED WITH ANTIVIRAL AND ANTI-INFLAMMATORY ACTIVITY ITALFARMACO SPA (IT) 1999-06-02 EP disclosed
US-5827881-A ADMINISTERING FOR TREATMENT OF VIRAL DISEASES OR AS ANTIINFLAMMATORY AGENTS ITALFARMACO S.P.A. (IT) 1998-10-27 US disclosed
EP-0748310-A1 DIESTERS OF CARBONIC ACID ENDOWED WITH ANTIVIRAL AND ANTI-INFLAMMATORY ACTIVITY ITALFARMACO S.p.A. (IT) 1996-12-18 EP disclosed
WO-1995023128-A1 DIESTERS OF CARBONIC ACID ENDOWED WITH ANTIVIRAL AND ANTI-INFLAMMATORY ACTIVITY ITALFARMACO S.P.A. (IT) 1995-08-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110070657-A1 DETECTING IONS AND MEASURING ION CONCENTRATIONS CA2, SLC30A5, CA3 CA12 68/4885CA1 36/4885CA9 188/4885
US-12540262-B2 Two component (2K) curable adhesive composition ILK, MAT2A, MMAB CA12 2296/4885CA1 1692/4885CA9 2943/4885
US-20260088410-A1 ELECTRONICS ASSEMBLY HAVING ELECTROCHEMICALLY DEBONDABLE COMPONENTS EPCAM, CDH1, ITGA4 CA12 2168/4885CA1 536/4885CA9 3002/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.